Abstract:Abstract Ulcerative Colitis (UC) and Crohn’s Disease (CD) are two major types of inflammatory bowel disease (IBD), with recurrent symptoms and significant morbidity. Long-term persistence of chronic inflammation in IBD is among the major factors contributing to neoplastic transformation and development of colitis-associated colorectal cancer. There is a lack of efficient medications for IBD, due to either limited efficacy or side effects. Antibodies against TNFα are effective therapies; however, they are expensive, and up to 40% of patients are non-responders. Thus, improved therapy with higher efficacy, enhanced safety and better patient affordability is urgently needed. The master regulator of innate immune response NFκB plays a critical role in the initiation and chronicity of IBD mucosal inflammation. We demonstrated that bromodomain-containing protein 4 (BRD4), an epigenetic reader, is required for stabilization of NFκB binding on the promoters of inflammatory genes, activation of RNA polymerase II, and histone H3 Lys122 acetylation (H3K122ac) to permit high levels of inflammatory gene expressions by sentinel epithelial cells and stromal fibroblasts. Our data using human IBD patient samples suggest that BRD4 activation is critical to the initiation of colonic inflammation. We have successfully identified highly potent and specific BRD4 inhibitors, demonstrating that inhibition of BRD4 suppresses expression of inflammatory cytokines TNFα, IL-6, IL-17A, and IL-8. Administration of our lead inhibitors (ZL0454 & ZL0420) significantly reduces initiation of the mucosal inflammation in both dextran sulfate sodium (DSS)-induced and Cbir1 T cell transfer colitis models in vivo, but with low toxicity and much safer than the generic NFκB/IKK inhibitor BMS345541. The levels of NFkB and BRD4 activation were also compared using immunofluorescence staining of NFkB/RelA translocation, phospho-Ser276 RelA formation, and induction of the BRD4 marker H3K122Ac. The BRD4 inhibitors reduced DSS-induced NFkB-BRD4 activation in colon tissue, demonstrating the target specificity in vivo. Our data suggest that BRD4 activation is critical to the initiation of the colonic inflammation during IBD. BRD4 inhibition disrupts its interactions with acetylated histone lysine residues, thereby blocking the pathological activation of the BRD4-NFκB signaling and suppressing colonic inflammation. Therefore, inhibition of the BRD4 activation is an attractive target for the development of novel IBD therapy and in prevention of CAC. Using our novel BRD4 inhibitors, we will further seek to evaluate the effect of long-term BRD4 inhibition on UC-induced neoplastic transformation and development of CAC. Funding support: Crohn’s & Colitis Foundation Entrepreneurial Investing (EI) Initiative award and a research fellowship award from the Crohn’s & Colitis Foundation of America.

Discovery of Potent and Selective BRD4 Inhibitors Capable of Blocking TLR3-induced Acute Airway Inflammation.

Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation

Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site

Efficacy of Novel Highly Specific Bromodomain-Containing Protein 4 Inhibitors in Innate Inflammation-Driven Airway Remodeling.

Inhibitors of BRD4 Protein from a Marine-Derived Fungus Alternaria Sp. NH-F6.

Pharmacoproteomics reveal novel protective activity of bromodomain containing 4 inhibitors on vascular homeostasis in TLR3-mediated airway remodeling

Selective Antagonists of the Bronchiolar Epithelial NF-κB-Bromodomain-Containing Protein 4 Pathway in Viral-Induced Airway Inflammation

Discovery of a novel BLT2 antagonist for the treatment of inflammatory airway diseases

Discovery of Pyrazolo[1,5- a ]pyrimidine Derivatives Targeting TLR4−TLR4* Homodimerization via AI-Powered Next-Generation Screening

Drug Discovery of Acetophenone Derivatives As BRD4 Inhibitors

Discovery of the Natural Product 3',4',7,8-Tetrahydroxyflavone As a Novel and Potent Selective BRD4 Bromodomain 2 Inhibitor.

Discovery of Orally Active 1,4,5,6,8-Pentaazaacenaphthylens As Novel, Selective, and Potent Covalent BTK Inhibitors for the Treatment of Rheumatoid Arthritis.

6 NOVEL BRD4 INHIBITORS BLOCK THE PATHOLOGICAL ACTIVATION OF BRD4-NFκB SIGNALING AND SUPPRESS COLONIC INFLAMMATION IN IBD MOUSE MODELS

Small-Molecule TLR8 Antagonists Via Structure-Based Rational Design.

Design, synthesis and anti-rheumatoid arthritis activity of target TLR4 inhibitors

Discovery of novel TLR4/MD-2 inhibitors: Receptor structure-based virtual screening studies and anti-inflammatory evaluation

Discovery of 4-Aminoquinoline-3-carboxamide Derivatives As Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis

Discovery Of 3,5-Dimethylisoxazole Derivatives As Novel, Potent Inhibitors For Bromodomain And Extraterminal Domain (Bet) Family

Discovery of Pyrazolo[1,5-Α]pyrimidine Derivatives Targeting TLR4-TLR4*homodimerization Via AI-powered Next-Generation Screening

Discovery and Optimization of 4-Oxo-2-thioxo-thiazolidinones As NOD-like Receptor (NLR) Family, Pyrin Domain-Containing Protein 3 (NLRP3) Inhibitors.

Selective, Tight-Binding Inhibitors of Integrin Alpha4beta1 That Inhibit Allergic Airway Responses.